4 Healthcare Stock Stories For a Weekend Investment Checkup
Epizyme, Inc. (NASDAQ:EPZM): Closing price $31.34
The firm said Friday that the FDA has granted orphan drug designation for EPZ-5676. Criteria for orphan drug designation mandates that the product be intended for treatment of a rare disease or condition, and classified as affecting fewer than 200,000 people in the United States. Epizyme is a clinical stage biopharmaceutical firm that creates innovative personalized therapeutics for patients having genetically defined cancers.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.